Company Operations by Product, Customer and Geographic Area

We have determined that we operate in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

The following table presents a summary of total revenues by these products for the twelve months ended December 31, 2019, 2018, and 2017:



Revenue by Product:	2019			2018		2017

Bloxiverz	$	7,479		$	20,850	$	45,596
Vazculep	33,152			42,916		38,187
Akovaz	18,642			33,759		80,617
Other	(58		)	3,898		8,441
Product sales	59,215			101,423		172,841
License revenue	—			1,846		404
Total revenues	$	59,215		$	103,269	$	173,245

Concentration of credit risk with respect to accounts receivable is limited due to the high credit quality comprising a significant portion of the Company’s customers. Management periodically monitors the creditworthiness of our customers and believes that we have adequately provided for any exposure to potential credit loss.

The following table presents a summary of total revenues by significant customer for the twelve months ended December 31, 2019, 2018, and 2017:



Revenue by Significant Customer:	2019		2018		2017

Cardinal Health	$	15,088	$	25,413	$	37,965
McKesson Corporation	14,900		26,794		44,762
AmerisourceBergen	12,059		18,620		25,691
Others	17,168		30,596		64,423
Product sales	59,215		101,423		172,841
License revenue	—		1,846		404
Total revenues	$	59,215	$	103,269	$	173,245

In 2017, 31% of product sales was sold to PharMedium. In 2018 and 2019, product sales to PharMedium was less than 10%.

As of December 31, 2019, the Company had three customers, each of which are substantial wholesale distributors, and accounted for 10% or more of the accounts receivable balance. One customer accounted for 40%, or $3,346, a second customer accounted for 29% or $2,416, and a third customer accounted for 11% or $949. As of December 31, 2019, the Company had no significant past due account receivable balances.

The following table summarizes revenues by geographic region for the twelve months ended December 31, 2019, 2018, and 2017:



Revenue by Geographic Region:	2019		2018		2017

U.S.	$	59,215	$	101,423	$	172,841
Ireland	—		1,846		404
Total revenues	$	59,215	$	103,269	$	173,245

Currently, we depend on a single contract manufacturing organization for the manufacture of Bloxiverz and Vazculep and two contract manufacturing organizations for the manufacture of Akovaz, from which we derive a majority of our revenues. Additionally, we purchase certain raw materials used in our products from a limited number of suppliers, including a single supplier for certain key ingredients.

Non-monetary long-lived assets primarily consist of property and equipment, goodwill and intangible assets. The following table summarizes non-monetary long-lived assets by geographic region as of December 31, 2019, 2018, and 2017:



Long-lived Assets by Geographic Region:	2019		2018		2017

U.S.	$	22,254	$	27,761	$	116,536
France	196		1,365		2,257
Ireland	7,244		6,028		1,360
Total	$	29,694	$	35,154	$	120,153